The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis

被引：0
作者：
O. G. Artamonova
A. E. Karamova
A. A. Nikonorov
D. A. Verbenko
E. L. Vasileva
A. A. Kubanov
机构：
[1] Ministry of Health of the Russian Federation,State Research Center for Dermatovenereology and Cosmetology
来源：
Bulletin of Experimental Biology and Medicine | 2021年 / 171卷
关键词：
psoriasis; tofacitinib; Janus kinase inhibitors; apremilast; phosphodiesterase-4 inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In patients with moderate-to-severe and severe psoriasis and high efficacy of therapy (PASI≥75) with signaling pathway inhibitors (apremilast, tofacitinib), cytokine spectra in the skin and blood plasma were studied using xMAP technology at baseline and on weeks 14 and 26 of treatment. Comparison of cytokine levels in psoriatic lesional skin and plasma samples of patients treated with apremilast or tofacitinib revealed statistical difference only for IFNγ level (р<0.05) at week 26.
引用
收藏
页码：208 / 211
页数：3
相关论文
共 96 条
  • [1] Bachelez H(2015)OPT Compare Investigators. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomized non-inferiority trial The Lancet. 386 552-561
  • [2] van de Kerkhof PC(2019)Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors Inflamm. Res. 68 557-567
  • [3] Strohal R(2018)Scanning the immunopathogenesis of psoriasis Int. J. Mol. Sci. 19 179-1013.e6
  • [4] Kubanov A(2018)Synergistic cytokine effects as apremilast response predictors in patients with psoriasis J. Allergy Clin. Immunol 142 1010-248
  • [5] Valenzuela F(2015)Simultaneous detection and quantification of six equine cytokines in plasma using a fluorescent microsphere immunoassay (FMIA) MethodsX. 2 241-421
  • [6] Lee JH(2002)Regulation of cytokine signaling and inflammation Cytokine Growth Factor Rev. 13 413-472
  • [7] Yakusevich V(2014)Serum levels of LL-37 and inflammatory cytokines in plaque and guttate psoriasis Mediators Inflamm. 2014 268257-42
  • [8] Chimenti S(2017)Apremilast: a review in psoriasis and psoriatic arthritis Drugs. 77 459-316
  • [9] Papacharalambous J(2020)Systemic treatment of psoriasis with JAK inhibitors: a review Dermatol. Ther. (Heidelb) 10 29-961
  • [10] Proulx J(2020)The effect of apremilast therapy on skin cytokine levels in patients with psoriasis Russ. Open Med. J. 9 310-49
12345678910